30 closest matches · ranked by relevance
Juvenile Pilocytic Astrocytomas · Optic Pathway Gliomas
Primary: Number of Children Responding to Treatment — 0; 0; 5 Participants
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Malignant Glioma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0 percentage of participants
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Glioma
Primary: RAD001 Response Rate Based on 2D MRI Change From Baseline — 15 participants — p=<0.001
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Brain Neoplasms
Primary: [18F] Fluorothymidine ([18F]-FLT) Uptake as a Marker of Cellular Proliferation — 1.57; 3.00 SUV max — p=< 0.001
Glioma · Low-grade Glioma · Astrocytoma
Primary: Overall Response — 2; 21 participants
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
Anaplastic Astrocytoma · Brain Stem Glioma · Childhood Mixed Glioma
Primary: Maximum-tolerated Dose of Veliparib Defined as Highest Dose Level With Fewer Than 2 Dose Limiting Toxicities in 6 Patients as Assessed by the National Cancer Institute…
Low-Grade Gliomas · Malignant Neoplasms, Brain · Soft Tissue Neoplasms
Primary: Best Overall Response Rate (Strata 1 and 2) — 15; 12 Participants
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose of Adavosertib — 200 mg/m^2
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Childhood Cerebellar Anaplastic Astrocytoma · Childhood Cerebral Anaplastic Astrocytoma · Childhood Cerebral Astrocytoma
Primary: Sustained Objective Response Rate — 0; 0 percentage of patients
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Diffuse Astrocytoma · Anaplastic Astrocytoma · Astrocytoma
Primary: LGG Cohort: Overall Response Rate (ORR) by Central Independent Assessment Using Response Assessment in Neuro-Oncology (RANO) Criteria — 46.6; 10.8 Percentage of…
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Glioma
Primary: Number of Patients Who Experienced Dose Limiting Toxicities (DLTs) — 0; 2; 0; 1 Participants
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001